Compare American International Group Inc (AIG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs TransMedics Group Inc — how do they compare? American International Group Inc trades at $76.46 (market cap $40.42B), while TransMedics Group Inc trades at $87.61 (market cap $3.10B). The key difference: American International Group Inc is far larger — about 13× TransMedics Group Inc's market cap, and American International Group Inc pays a 2.59% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AIG | TMDX | |
|---|---|---|
Market Cap | $40.42B | $3.10B |
Sector | Financials | Technology |
52-Week High | $86.59 | $150.42 |
52-Week Low | $71.89 | $61.99 |
Enterprise Value | $48.06B | $3.49B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.42, down 1.53% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with $2.11 EPS versus $1.89 expected, driven by robust underwriting income. Revenue for 2025 was $26.77B with net income of $3.10B, yielding an 11.12% net margin. The stock carries a P/E of 14.11 and a consensus analyst price target of $89.00, suggesting potential upside from current levels.
The outlook for AIG is mixed; solid earnings performance and a diversified insurance portfolio support growth, but competitive pricing pressure and investment income headwinds pose risks. With 39% of analysts rating it a Buy, the stock appears undervalued relative to its price target, though near-term catalysts may be limited amid broader market volatility.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
